While hysterectomies and major surgeries once dominated fibroid treatment, women now have an arsenal of less invasive options that don’t require going under the knife. Yet somehow, many doctors still default to the old playbook. Why?
Take uterine artery embolization. This catheter-based procedure blocks blood flow to fibroids, shrinking them by 20% to 60%. Patients see sustained improvement for at least three years, and many avoid hysterectomy altogether. The recurrence rate? Just 23% over ten years. Not bad for keeping your uterus intact.
Uterine artery embolization shrinks fibroids up to 60% with just 23% recurrence over ten years—no hysterectomy required.
Then there’s MRI-guided focused ultrasound, which sounds like science fiction but actually exists. High-intensity ultrasound thermally destroys fibroid tissue without a single incision. No general anesthesia needed. Quick recovery. Perfect for women who can’t handle surgery or anesthesia. But here’s the kicker—access is restricted, costs are high, and it only works for specific fibroid types. Similar to how geographic disparities affect disease treatment globally, access to this technology varies significantly by region.
Radiofrequency ablation targets fibroids through small incisions or transcervical access. Outpatient procedure, rapid recovery, uterus stays put. Women love it because fertility remains an option. The downside? It doesn’t work well for large or multiple fibroids, and availability is limited because it’s newer technology.
Medical therapy offers another route entirely. GnRH antagonists, selective progesterone receptor modulators, progestin-releasing IUDs, tranexamic acid—these medications control symptoms and shrink fibroids with relatively few side effects. The FDA even approved oral GnRH antagonists specifically for symptomatic fibroids. But stop taking them, and symptoms often return.
Emerging treatments show even more promise. Collagenase injections directly into fibroids reduce pain and volume in pilot studies. Imagine this: a simple office procedure using ultrasound guidance. Low cost, minimal fuss. New gel-based drug delivery systems could make localized treatment last longer.
Researchers are investigating vitamin D and green tea extract for symptom control, though evidence remains limited. Some innovations specifically target health inequities by improving access in underserved areas. Despite myomectomy proving more cost-effective, doctors continue to recommend hysterectomies for many patients. Despite these advances, fibroids still account for 40%-60% of hysterectomies performed, suggesting doctors haven’t fully embraced these alternatives.
